Category: Corporate NewsBy adminNovember 28, 2023 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Rameda 3Q23 BOD Meeting MinutesNextNext post:BOD-Shareholding -Structure 2023Related PostsRameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024Rameda 4Q23 Earnings ReleaseMarch 20, 2024Rameda Reports its 3Q23 ResultsNovember 14, 2023Equinox Pharma Holding Limited (Equinox) increases stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.November 6, 2023Rameda Reports its 2Q23 ResultsAugust 15, 2023Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. finalizes acquisition of a portfolio of 11 fast-growing cardiometabolic productsJune 1, 2023
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
Equinox Pharma Holding Limited (Equinox) increases stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.November 6, 2023
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. finalizes acquisition of a portfolio of 11 fast-growing cardiometabolic productsJune 1, 2023
